Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

Müller, Norbert; Krause, Daniela; Dehning, Sandra; Musil, Richard; Schennach-Wolff, Rebecca; Obermeier, Michael; Möller, Hans‐Jürgen; Klauß, Volker; Schwarz, Markus J.; Riedel, Michael

doi:10.1016/j.schres.2010.04.015

Cited by 232 publications

(170 citation statements)

References 37 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…When translating these findings into clinical trials, initial studies have shown a positive effect of medication targeting the immune system when used as an add-on treatment to antipsychotics (4)(5)(6). To aid further development of this therapeutic approach, tools for directly assessing the status of the brain immune system are needed to allow for patient stratification and monitoring of treatment effects.…”

mentioning

confidence: 99%

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Plavén-Sigray

Matheson

Collste

et al. 2018

Biological Psychiatry

110

102

View full text Add to dashboard Cite

BACKGROUND: Accumulating evidence suggests that the immune system may be an important target for new treatment approaches in schizophrenia. Positron emission tomography and radioligands binding to the translocator protein (TSPO), which is expressed in glial cells in the brain including immune cells, represents a potential method for patient stratification and treatment monitoring. This study examined whether patients with first-episode psychosis and schizophrenia had altered TSPO levels compared with healthy control subjects. METHODS: PubMed was searched for studies comparing patients with psychosis with healthy control subjects using second-generation TSPO radioligands. The outcome measure was total distribution volume (V T ), an index of TSPO levels, in frontal cortex, temporal cortex, and hippocampus. Bayes factors (BFs) were applied to examine the relative support for higher, lower, or no difference in patients' TSPO levels compared with healthy control subjects. RESULTS: Five studies, with 75 participants with first-episode psychosis or schizophrenia and 77 healthy control subjects, were included. BFs showed strong support for lower V T in patients relative to no difference (all BFs .

show abstract

mentioning

confidence: 99%

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Plavén-Sigray

Matheson

Collste

et al. 2018

Biological Psychiatry

110

102

View full text Add to dashboard Cite

show abstract

“…Two more, both from the same team [14,15], found small benefits on some outcome measures, but the results at the study end point were statistically significant in only one of these [15]. In the other [14], acceleration of response was observed, but no statistically significant separation of groups was found at the end of the study.…”

mentioning

confidence: 90%

Anti-inflammatory strategies in the treatment of schizophrenia

Andrade

2015

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

“…It was demonstrated that the modulation of COX activity with anti-inflammatory agents such as aspirin [41] and celecoxib [42,43] as adjunctive therapy to antipsychotics, may improve symptoms in SCZ. 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) is a COX-derived product that exerts its anti-inflammatory effect by targeting peroxisome proliferator-activated receptor-gamma (PPAR-γ) [44].…”

Section: Immunoinflammatory Biomarkersmentioning

confidence: 99%

Biomarkers and schizophrenia: a qualitative review

Silva¹,

Pinto²

2017

IJCNMH

View full text Add to dashboard Cite

Schizophrenia (SCZ) is a psychiatric disorder with a broad spectrum of biological and clinical manifestations of yet not completely clear pathophysiological mechanisms. Several lines of evidence have been supporting the idea that immunoinflammatory, oxidative, hormonal and cellular dysfunctions are implicated on the biomolecular basis of SCZ. However, accurate diagnosis and selection of appropriate treatments remains challenging as a result of the scarcity of objective tests. Furthermore, there is a compelling need to find biomarkers that could predict drug response and tailor pharmacological treatment, particularly in drug-naïve first episode psychosis (FEP). Hence, numerous technologies have been employed in order to search for SCZ biological markers, but evidence relating them to treatment efficacy is lacking. In this regard, some preliminary data suggest promising results. The current review provides information on: (1) potential biomarkers associated with biological disturbances and (2) biological markers associated with treatment response.

show abstract

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

Cited by 232 publications

References 37 publications

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Anti-inflammatory strategies in the treatment of schizophrenia

Biomarkers and schizophrenia: a qualitative review

Contact Info

Product

Resources

About